Electrical Stimulation for Pain Management
I know in my own case that its clear how that predisposition manifested itself the first time I ever got drunk. My friend and I were 11 years old. We stole alcohol from the bar of a rented moved here ski cabin up in Tahoe, mixing small amounts of the different liquors in a Snapple bottle so the grownups wouldnt notice any was missing. For me its an old story at this pointpractically a legend. I drank some, he drank some. He hated the way it tasted and stopped. I loved the way it made me feel and drank the whole goddamn thingand then I puked for like an hour. Something in my brain was turned on that night after feeling the very first effects of that alcohol. Some switch had been flipped. And, as I would come to learn later, that switch would get flipped on whenever I took drugs or alcohol into my system. Because once I started, I couldnt stop.
For the original version including webpage any supplementary images or video, visit http://www.salon.com/2012/11/08/pain_management/
Pain Management Treatment Markets
Learn how it works and whether it’s considered effective. Medically reviewed by Pat F. Bass III, MD, MPH Transcutaneous electrical nerve stimulation, or TENS, is a pain management technique that uses electricity to help alleviate pain. TENS has been a commonly used pain management therapy almost since it was first developed in the late 1960s. But like some other therapies, TENS results arent guaranteed some people find TENS more helpful than others. TENS treatment involves placing small electrodes, devices that conduct electricity, on the skin over the part of the body that’s in pain; they are held in place with adhesive. The electrodes are then attached to a machine that releases small waves of electricity, sending tiny electrical impulses through the electrodes to the painful joint or area of the body. TENS for Pain Management: How It Works How does electricity alleviate pain? It’s thought that the electrical impulses interrupt messages about pain sent from the nerves to the brain. The electricity blocks the activity of the pain receptors, which send those pain messages .
For the original version including any supplementary images or video, visit http://www.everydayhealth.com/pain-management/electrical-stimulation-therapies.aspx
BioDelivery Sciences Announces Regulatory Approval of ONSOLIS in Taiwan
Finance Mon, Jul 29, 2013, 8:09 AM EDT – U.S. Markets open in 1 hr 21 mins Pain Management Treatment Markets http://www.reportlinker.com/p01138845/Pain-Management-Treatment-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine Pain management describes a particular set of drugs, analgesics, which are specifically used as therapeutics to control pain in the clinic. As pain affects 1.5 billion people worldwide, these drugs are one of the major segments of the central nervous system (CNS) therapies market. This TriMark Publications report focuses on the role of pain management drugs in clinical use and in drug development for acute pain, chronic pain, neuropathic path and nociceptive pain. The report discusses drug development and targeted therapeutics, as well as their use in clinical trials. New approaches meant to aid in development of drugs for therapeutic use are emphasized. The study also analyzes almost all of the major, specialty and emerging companies known to be marketing, manufacturing or developing pain management treatment products in the U.S. and worldwide. Additionally, this review provides detailed tables, charts and figures with past and projected sales data for the U.S., Europe and other geographic regions. TABLE OF CONTENTS 1.1 Statement of Report 6 1.2 About this Report 6 1.3 Scope of the Report 6 1.4 Objectives 6 Table 2.1: Treatment Recommendations for Osteoarthritic Pain 17 Table 2.2: Competitive Landscape for Postoperative Pain Management 21 Table 2.3: A Suggested Stepwise Approach to Treating Neuropathic Pain 25 Table 2.4: EULAR Recommendations for Treating Fibromyalgia 25 Table 2.5: Remoxy Versus OxyContin OC 32 Table 3.1: Branded Opioid Formulations and their Estimated 2012 Sales 41 Table 3.2: The More Widely Used NSAIDs 43 Table 3.4: 2012 U.S.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/pain-management-treatment-markets-190500471.html
Finance Mon, Jul 29, 2013, 8:09 AM EDT – U.S. Markets open in 1 hr 21 mins BioDelivery Sciences Announces Regulatory Approval of ONSOLIS in Taiwan Press Release: BioDelivery Sciences International, Inc. 1 hour 9 minutes ago BDSI 4.70 RALEIGH, N.C., July 29, 2013 /PRNewswire/ –BioDelivery Sciences International, Inc. ( BDSI ) announced the regulatory approval of ONSOLIS in Taiwan for the management of breakthrough cancer pain in opioid tolerant, adult patients with cancer. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) In Taiwan, BDSI has licensed the commercialization rights to TTY Biopharm, where the product will be marketed under the brand name PAINKYL. TTY will be responsible for the cost of future product commercialization in Taiwan and expects to launch PAINKYL following receipt of reimbursement pricing from the Taiwanese national healthcare system. The approval in Taiwan results in a milestone payment of $300,000 to BDSI. Upon launch, BDSI will receive a royalty on net sales. “We offer our thanks and congratulations to our partner TTY on the regulatory approval for this product, which will be the first drug available in Taiwan for the treatment of breakthrough cancer pain,” said Dr. Andrew Finn, Executive Vice President of Product Development at BDSI. ONSOLIS is approved in the U.S. and Canada for the treatment of breakthrough pain in opioid-tolerant adult patients with cancer and marketed in the E.U. as BREAKYL. The commercialization rights are licensed to Meda for all territories world-wide with the exception of Taiwan and South Korea. In South Korea, the product is licensed to Kunwha Pharmaceutical Co. About BioDelivery Sciences International BioDelivery Sciences International ( BDSI ) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction. BDSI’s pain franchise currently consists of three products, two of which utilize the patented BioErodible MucoAdhesive (BEMA) drug delivery technology. ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/biodelivery-sciences-announces-regulatory-approval-110000939.html